Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) CEO Dr Vladislav Sandler talked with Proactive about the company's recent operations update. In the interview, Sandler detailed three key areas of focus: the HEMO-CAR-T program, the CBR platform, and CDX bispecific antibodies.
Starting with the HEMO-CAR-T program, Hemogenyx has added an additional clinical trial site at a prestigious US medical center. Sandler emphasised that this expansion will enhance the trial's scope and speed up the timeline. He also revealed plans to include pediatric indications, potentially transforming treatment options for children with acute myeloid leukemia and acute lymphoblastic leukaemia.
Sandler provided insights into the CBR (Chimeric Bait Receptor) platform, describing it as an advanced immunotherapy aimed at reprogramming innate immune cells to combat infections and certain cancers. The platform is in the development and testing phase, with promising results so far.
Lastly, Dr Sandler discussed progress with KD bispecific antibodies, developed initially for treating relapsed refractory acute myeloid leukemia. Hemogenyx is advancing this candidate through INDe-enabling studies, highlighting its potential in bone marrow transplant conditioning and pediatric indications.
"We have a chance to make a real difference in the lives of these kids and their families," said Dr Sandler, underlining the company's commitment to pioneering new treatments.
